BMI, Adiposity & Tirzepitide and HFpFF; BAV-0 and Aortic Stenosis; Infective Endocarditis and Mitral Valve Replacement

In this week's View, Dr. Eagle looks at the SUMMIT trial and considers how body mass index (BMI) and central adiposity affect tirzepatide outcomes for heart failure with preserved ejection fraction (HFpEF). He then discusses bicuspid aortic valves type 0 (BAV-0) and its association with better long-term prognosis in patients with severe aortic stenosis (AS) undergoing tricuspid aortic valve replacement (TAVR). Finally, Dr. Eagle examines long-term risk of infective endocarditis and why it is significantly higher for mitral valve (MV) replacement versus repair.

Subscribe to Eagle's Eye View